 BEDMER, N.J.--BUSINESS WIRE--TYME Technologies, Inc. Nasdaq: TYME the Company or Tyme, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, today announced that its abstract featuring data from the Companys investigational therapy, SM-88, has been selected for publication at the American Society of Clinical Oncology ASCO Annual Meeting being held virtually June 4-8, 2021. Details about the abstract selected for publication can be found below: 